Literature DB >> 17986664

Social participation of patients with hemophilia in the Netherlands.

Iris Plug1, Marjolein Peters, Eveline P Mauser-Bunschoten, Arja de Goede-Bolder, Lily Heijnen, Cees Smit, José Willemse, Frits R Rosendaal, Johanna G van der Bom.   

Abstract

The introduction of replacement therapy in the 1960s has improved medical and social circumstances gradually. The availability of prophylactic treatment has further increased the possibilities of a "normal" life for patients with hemophilia. We examined whether social participation and health-related quality of life (HRQol) of today's hemophilia patients differs from the general male population. There were a total of 721 participants in the Hemophilia in the Netherlands 5 study (HiN-5 study) ages 16 to 64 years. Patients with severe hemophilia participated less in full-time work compared with the general population. Occupational disability was reported by 35% of patients with severe hemophilia between ages 31 and 64 years, compared with 9% in the general population. HRQol of patients with severe hemophilia between ages 31 and 64 years was lower than of the general population. The differences with the general population in HRQol were least pronounced for patients between ages 16 and 30 years. Despite major improvements in treatment during the last decades, patients with hemophilia are still less involved in full-time paid work and suffer more from occupational disability than men from the general population. After the introduction of prophylactic treatment, the number of patients who are occupationally disabled is reduced.

Entities:  

Mesh:

Year:  2007        PMID: 17986664     DOI: 10.1182/blood-2007-07-102202

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Exploring the diversity of conceptualizations of work (dis)ability: a scoping review of published definitions.

Authors:  Valérie Lederer; Patrick Loisel; Michèle Rivard; François Champagne
Journal:  J Occup Rehabil       Date:  2014-06

2.  The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease.

Authors:  Séverine Henrard; Brecht Devleesschauwer; Philippe Beutels; Michael Callens; Frank De Smet; Cedric Hermans; Niko Speybroeck
Journal:  Orphanet J Rare Dis       Date:  2014-03-21       Impact factor: 4.123

3.  Obstacles and future of gene therapy for hemophilia.

Authors:  Valder R Arruda; Ben J Samelson-Jones
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-18       Impact factor: 0.694

4.  Economic burden of high-responding inhibitors in patients with hemophilia A in Taiwan.

Authors:  Tsu-Chiang Tu; Shin-Nan Cheng; Jye-Daa Chen; Thau-Ming Cham; Mei-Ing Chung
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

5.  Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan.

Authors:  Tsu-Chiang Tu; Wen-Shyong Liou; Tsui-Yun Chou; Tsung-Kun Lin; Chuan-Fang Lee; Jye-Daa Chen; Thau-Ming Cham; Mei-Ing Chung
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

6.  Psychological interventions for people with hemophilia.

Authors:  Laura Palareti; Giannino Melotti; Frederica Cassis; Sarah J Nevitt; Alfonso Iorio
Journal:  Cochrane Database Syst Rev       Date:  2020-03-18

7.  Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study.

Authors:  Laura Palareti; Silvia Potì; Frederica Cassis; Francesca Emiliani; Davide Matino; Alfonso Iorio
Journal:  Int J Qual Stud Health Well-being       Date:  2015-11-16

8.  Pain Experience in Hemophilia Patients: A Hermeneutic Phenomenological Study.

Authors:  Masoume Rambod; Farkhondeh Sharif; Zahra Molazem; Kate Khair
Journal:  Int J Community Based Nurs Midwifery       Date:  2016-10

9.  Health-related quality of life, developmental milestones, and self-esteem in young adults with bleeding disorders.

Authors:  P F Limperg; L Haverman; H Maurice-Stam; M Coppens; C Valk; M J H A Kruip; J Eikenboom; M Peters; M A Grootenhuis
Journal:  Qual Life Res       Date:  2017-09-12       Impact factor: 4.147

10.  The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.

Authors:  Carolyn E Schwartz; Victoria E Powell; Jun Su; Jie Zhang; Adi Eldar-Lissai
Journal:  Qual Life Res       Date:  2018-02-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.